12:00 AM
 | 
Feb 09, 2009
 |  BC Week In Review  |  Company News  |  Deals

Cephalon, ImmuPharma deal

Cephalon exercised its option to license exclusive, worldwide rights to ImmuPharma's Lupuzor (formerly IPP-201101) to treat systemic lupus erythematosus (SLE). ImmuPharma will receive a $30 million one-time...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >